Dermatology · Ohio
Dermatology and skin studies in Ohio
42 studies have at least one recruiting site in Ohio. Skin studies test treatments for conditions such as psoriasis, eczema, acne, alopecia, vitiligo and hidradenitis suppurativa, from creams to tablets and injections.
42 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Sitryx Therapeutics Ltd
- Location
- Boardman, OH + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Cleveland, OH + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- Fairborn, OH + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
- Location
- Boardman, OH + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Boardman, OH + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Bexley, OH + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie
- Location
- Cleveland, OH + 29 other US sites
- Eligibility basics
- Ages 12–63
- RecruitingPhase 1
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Mayfield Heights, OH
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- Boardman, OH + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 1
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc.
- Location
- Mayfield Heights, OH + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Cleveland, OH + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Cincinnati, OH + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Canton, OH + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Boardman, OH + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Novartis Pharmaceuticals
- Location
- Boardman, OH + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Novartis Pharmaceuticals
- Location
- Mayfield Heights, OH + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Bexley, OH + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
LEO Pharma
- Location
- Mayfield Heights, OH + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC
- Location
- Cincinnati, OH + 5 other US sites
- Eligibility basics
- Ages 3+
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Canton, OH + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
Janssen Research & Development, LLC
- Location
- Middleburg Heights, OH + 17 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
ARS Pharmaceuticals, Inc.
- Location
- Cincinnati, OH + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
HCW Biologics
- Location
- Columbus, OH + 2 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Beavercreek, OH + 65 other US sites
- Eligibility basics
- Ages 2–11
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Do I need a diagnosis to join a skin study?
Usually yes, and the site will confirm it at screening. Some studies also recruit people without the condition as a comparison group.